(S (S (NP (NP (NNP Knee) (NN osteoarthritis)) (PRN (-LRB- -LRB-) (NP (NNP OA)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (JJ musculoskeletal) (NN disease)) (PP (IN without) (NP (DT a) (NN cure)))))) (, ,) (CC and) (S (NP (JJ current) (NN treatment) (NNS options)) (VP (VBP are) (VP (VBN limited) (PP (TO to) (NP (JJ symptomatic) (NN relief)))))) (. .))
(S (S (NP (NP (NN Prediction)) (PP (IN of) (NP (NNP OA) (NN progression)))) (VP (VBZ is) (NP (DT a) (ADJP (RB very) (JJ challenging) (CC and) (JJ timely)) (NN issue)))) (, ,) (CC and) (S (NP (PRP it)) (VP (MD could) (, ,) (SBAR (IN if) (S (VP (VBN resolved)))) (, ,) (VP (VP (VB accelerate) (NP (DT the) (ADJP (NN disease) (VBG modifying)) (NN drug) (NN development))) (CC and) (VP (ADVP (RB ultimately)) (NN help) (S (VP (TO to) (VP (VB prevent) (NP (NP (NNS millions)) (PP (IN of) (NP (NP (JJ total) (JJ joint) (NN replacement) (NNS surgeries)) (VP (VBN performed) (ADVP (RB annually))))))))))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (NP (DT a) (JJ multi-modal) (ADJP (NN machine) (JJ learning-based)) (NNP OA) (NN progression) (NN prediction) (NN model)) (SBAR (WHNP (WDT that)) (S (VP (VBZ utilizes) (NP (NP (JJ raw) (JJ radiographic) (NNS data)) (, ,) (NP (JJ clinical) (NN examination) (NNS results)) (CC and) (NP (NP (JJ previous) (JJ medical) (NN history)) (PP (IN of) (NP (DT the) (NN patient)))))))))) (. .))
(S (NP (PRP We)) (VP (VBD validated) (NP (DT this) (NN approach)) (PP (IN on) (NP (NP (DT an) (JJ independent) (NN test) (NN set)) (PP (IN of) (NP (NP (CD 3,918) (NNS knee) (NNS images)) (PP (IN from) (NP (CD 2,129) (NNS subjects)))))))) (. .))
(S (NP (PRP$ Our) (NN method)) (VP (VBN yielded) (NP (NP (NP (NN area)) (PP (IN under) (NP (NP (DT the) (NNP ROC) (NN curve)) (PRN (-LRB- -LRB-) (NP (NNP AUC)) (-RRB- -RRB-)))) (PP (IN of) (NP (NP (CD 0.79)) (PRN (-LRB- -LRB-) (NP (NN 0.78-0.81)) (-RRB- -RRB-))))) (CC and) (NP (JJ Average) (NNP Precision) (PRN (-LRB- -LRB-) (NP (NNP AP)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (CD 0.68)) (PRN (-LRB- -LRB-) (NP (NN 0.66-0.70)) (-RRB- -RRB-))))))) (. .))
(S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT a) (NN reference) (NN approach)) (, ,) (PP (VBN based) (PP (IN on) (NP (JJ logistic) (NN regression)))) (, ,)) (VP (VBD yielded) (NP (NP (NP (NNP AUC)) (PP (IN of) (NP (NP (CD 0.75)) (PRN (-LRB- -LRB-) (NP (NN 0.74-0.77)) (-RRB- -RRB-))))) (CC and) (NP (NP (NNP AP)) (PP (IN of) (NP (NP (CD 0.62)) (PRN (-LRB- -LRB-) (NP (NN 0.60-0.64)) (-RRB- -RRB-))))))) (. .))
(S (NP (DT The) (VBN proposed) (NN method)) (VP (MD could) (VP (VP (ADVP (RB significantly)) (VB improve) (NP (NP (DT the) (JJ subject) (NN selection) (NN process)) (PP (IN for) (NP (NNP OA) (JJ drug-development) (NNS trials))))) (CC and) (VP (VB help) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (VBN personalized) (JJ therapeutic) (NNS plans))))))) (. .))
